Bacterial infection of lung airways underlies some of the main complications of COPD, including acute exacerbations, which significantly impact disease progression and outcome. Furthermore, airway (and parenchymal) colonization by bacteria and viruses may synergize, amplify, or trigger pathways of tissue damage started by cigarette smoke, leading to airway inflammation with remodeling and alveolar destruction. The present application is centered on the concept that bacteria populations present in the lung of smokers interact with environmental stresses triggered by cigarette smoke and pollutants to cause lung injury, including lung inflammation and apoptotic cell death. To this end, we have relied on amplification and sequencing of the bacterial small subunit ribosomal RNA (SSU-rRNA) gene in a large number of phenotypically and clinically well-characterized COPD lung samples, allowing us to identify bacteria populations present in smokers'and COPD diseased lungs, notably of Novosphingobium ssp, in extensive preliminary studies leading to this application. Furthermore, we also detected Novosphingobium spp DNA in extracts of the Marlboro" commercial cigarettes and in mouse lungs exposed to cigarette smoke. In this proposal, we hypothesize that the COPD lung harbors specific microbial communities, which segregate in specific lung compartments (airway vs. alveolus). In particular, we seek to demonstrate that Novosphingobium spp, identified in our ongoing microbiome studies, may be acquired through the inhalation of cigarette smoke and in the lung, trigger the activation of cytotoxic immunity against pulmonary cells associated with increased cytokine production in the setting of cigarette smoke exposure.
Specific Aim 1 will demonstrate that human lungs exposed to cigarette smoke contain Novosphingobium spp, which are present in cigarettes and transmitted into hosts through cigarette smoke exposure. Using a sensitive qPCR, we will test whether levels of Novosphingobium spp DNA increase with COPD disease severity.
Specific Aim 2 will determine the segregation of Novosphingobium spp and potentially relevant microbiota in anatomic lung compartments, such as the airways and alveolated tissue, in patients with COPD, smokers with minimal or mild disease, and in normal lungs using laser capture microdissection.
Specific Aim 3 will address whether Novosphingobium infection of alveolar epithelial cells can lead to activation of NK, and/or CD8 T cells via enhanced expression of NKG2D ligands, leading to killing of infected alveolar epithelial cells and/or interferon-3 production as evidence of cell activation. This potentially high-impact proposal fulfills the premises of the R21 funding mechanism in that the elucidation of the presence and types of lung bacterial populations in different stages of COPD may reveal important insights into the pathobiology of the disease. Notably, our studies may indicate that the potential activation of innate and acquired immunity triggered by bacterial products and chronically injured lung cells and structures may trigger auto-immunity, which contribute to alveolar cell death and lung destruction.

Public Health Relevance

Bacterial infection of lung airways underlies some of the main complications of COPD, which is a disease caused by cigarette smoke and characterized by progressive difficulty in breathing. Patients with severe COPD are at risk of getting worse and being infected by viruses and bacteria. These are called exacerbations, which cause patients to be hospitalized and received antibiotics and drugs that suppress the immune system. These patients are then at a significantly increased risk of death and marked clinical worsening of the shortness of breath. The proposed study is a novel way to find out whether there are bacteria present in small airway tubes in patients with COPD. We propose to use the lung tissues collected by the LTRC and translate a novel and quite "cool" method to perform a large scale screen of the bacteria that may be present in normal and diseased lungs. Our preliminary studies have revealed that the lungs of patients with COPD and also smokers with mild or no disease have bacteria called Novosphingobium. This bacteria is usually found in soil and water;however, it has been linked to an auto-immune destruction of the liver called primary biliary cirrhosis. Furthermore, Novosphingobium can digest substances present in the tobacco. Our proposal seeks to quantify these bacteria in lung samples in which the DNA has been selectively extracted from particular lung regions. Moreover, we also propose to initiate studies to show how the infection by Novosphingobium can accelerate damage of lung cells by inflammatory cells.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL110721-01A1
Application #
8258180
Study Section
Special Emphasis Panel (ZRG1-CVRS-G (03))
Program Officer
Punturieri, Antonello
Project Start
2011-12-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
1
Fiscal Year
2012
Total Cost
$216,250
Indirect Cost
$66,250
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Rutebemberwa, Alleluiah; Stevens, Mark J; Perez, Mario J et al. (2014) Novosphingobium and its potential role in chronic obstructive pulmonary diseases: insights from microbiome studies. PLoS One 9:e111150